marijuana stocks

InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work

Under the terms of the grant, the NSERC has committed funding of C$136,000 towards the Collaboration over the course of three years.  The Collaboration, entitled ‘Microbial metabolic engineering for cannabinoid biosynthesis’, which originally commenced in May 2015, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical needs.

InMed’s Vice President, Pre-Clinical Research & Development, Eric Hsu, Ph.D., commented, “We are honored that our trusted, world-class research partner, Dr. Yadav at UBC, has received this prestigious grant from the NSERC.  Through our continued research effort on this program with UBC, we remain optimistic that the development of our proprietary biosynthesis platform technology will result in commercial-scale manufacturing of cannabinoids.”

“We would like to take this opportunity to extend our gratitude to the NSERC for their vote of confidence in our cutting-edge work,” added Vikramaditya G. Yadav, Ph.D., Assistant Professor in the Department of Chemical & Biological Engineering.  “The successful completion of this Collaboration will not only advance the Company’s manufacturing capabilities and its R&D pipeline, but also provide immense social and strategic benefit to Canada.”

About InMed:
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.  InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

About Natural Sciences and Engineering Research Council of Canada (“NSERC”):
NSERC invests over $1.2 billion each year in natural sciences and engineering research in Canada.  Its investments deliver discoveries – valuable world-firsts in knowledge claimed by a brain trust of over 11,000 professors.  Its investments enable partnerships and collaborations that connect industry with discoveries and the people behind them.  Researcher-industry partnerships supported by NSERC help inform research and development and solve scale-up challenges.  NSERC also provides scholarships and hands-on training experience for more than 30,000 post-secondary students and post-doctoral fellows. These young researchers will be the next generation of science and engineering leaders in Canada.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Jushi Holdings Inc. (JUSHF) Reports Second Quarter 2022 Financial Results

Jushi Holdings Inc. Reports Second Quarter 2022 Financial Results and Announces Non-Reliance…

$BLPG Ensures Safe Lawful Cannabis Operations

Blue Line Protection Group Ensures Safe Lawful Cannabis Operations in Downtown Denver…

$NDEV Achieves Higher Anticipated Results

Novus Digital Marketing Achieves Higher Anticipated Results  Novus Acquisition & Development Corp.…

Cronos Group Inc. (CRON) Announces C$2.4 Billion Strategic Investment from Altria Group, Inc

Cronos Group Inc. Announces C$2.4 Billion Strategic Investment from Altria Group, Inc.…